NASDAQ:UBX Unity Biotechnology Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Unity Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.63 +0.07 (+12.50%) (As of 07/1/2022 03:59 PM ET) Add Compare Share Today's Range$0.56▼$0.6350-Day Range$0.56▼$0.9752-Week Range$0.55▼$4.97Volume505 shsAverage Volume671,506 shsMarket Capitalization$43.58 millionP/E RatioN/ADividend YieldN/APrice Target$6.40 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Unity Biotechnology MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside915.9% Upside$6.40 Price TargetShort InterestHealthy0.75% of Float Sold ShortDividend StrengthN/ASustainability-0.60Upright™ Environmental ScoreNews Sentiment-0.04Based on 3 Articles This WeekInsider TradingSelling Shares$12,055 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.10) to ($1.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.75 out of 5 starsMedical Sector797th out of 1,427 stocksBiotechnology Industry1st out of 7 stocks 3.5 Analyst's Opinion Consensus RatingUnity Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.40, Unity Biotechnology has a forecasted upside of 915.9% from its current price of $0.63.Amount of Analyst CoverageUnity Biotechnology has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.75% of the float of Unity Biotechnology has been sold short.Short Interest Ratio / Days to CoverUnity Biotechnology has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Unity Biotechnology has recently increased by 0.79%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldUnity Biotechnology does not currently pay a dividend.Dividend GrowthUnity Biotechnology does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUnity Biotechnology has received a 74.69% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for mental health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Unity Biotechnology is -0.60. Previous Next 1.1 News and Social Media Coverage News SentimentUnity Biotechnology has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Unity Biotechnology this week, compared to 0 articles on an average week.Search InterestOnly 3 people have searched for UBX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Unity Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -74% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Unity Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,055.00 in company stock.Percentage Held by InsidersOnly 6.80% of the stock of Unity Biotechnology is held by insiders.Percentage Held by InstitutionsOnly 21.22% of the stock of Unity Biotechnology is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Unity Biotechnology are expected to decrease in the coming year, from ($1.10) to ($1.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Unity Biotechnology is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Unity Biotechnology is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive UBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Unity Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address About Unity Biotechnology (NASDAQ:UBX) StockUnity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.Read More UBX Stock News HeadlinesJune 11, 2022 | americanbankingnews.comUnity Biotechnology, Inc. (NASDAQ:UBX) Receives $6.33 Consensus Price Target from AnalystsJune 10, 2022 | americanbankingnews.comUnity Biotechnology, Inc. Expected to Earn FY2023 Earnings of ($0.97) Per Share (NASDAQ:UBX)July 4, 2022 | Vantage Point (Ad)How You Should Be Choosing Your StocksGrab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2. May 26, 2022 | finance.yahoo.comUNITY Biotechnology Announces Appointment of Accomplished Finance and Operations Executive Michael Samar to the Board of DirectorsMay 10, 2022 | finance.yahoo.comUNITY Biotechnology, Inc. Reports First Quarter 2022 Financial Results and Business UpdatesMay 5, 2022 | finance.yahoo.comUNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular DiseasesApril 21, 2022 | finance.yahoo.comUNITY Biotechnology to Present Clinical Data at the Association for Research in Vision & Ophthalmology (ARVO) 2022 Annual MeetingApril 19, 2022 | seekingalpha.comUNITY Biotech doses first patient in phase 2 study of UBX1325 for chronic eye disorder wAMDJuly 4, 2022 | Vantage Point (Ad)How You Should Be Choosing Your StocksGrab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2. April 19, 2022 | finance.yahoo.comUNITY Biotechnology Doses First Patient in ENVISION, the Phase 2 Study of UBX1325 in Wet Age-Related Macular DegenerationApril 12, 2022 | finance.yahoo.comUNITY Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular EdemaMarch 17, 2022 | morningstar.comUnity Biotechnology Inc UBXMarch 17, 2022 | finance.yahoo.comInvestors in Unity Biotechnology (NASDAQ:UBX) from three years ago are still down 88%, even after 23% gain this past weekMarch 16, 2022 | benzinga.comUnity Biotechnology Files For Shelf Offering Of Up To $125MMarch 15, 2022 | seekingalpha.comUnity Biotechnology files for $125M mixed shelf offering; shares up 19%March 15, 2022 | seekingalpha.comUnity Biotechnology GAAP EPS of -$0.18 beats by $0.18, revenue of $4.78MMarch 15, 2022 | finance.yahoo.comUNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Business UpdatesMarch 1, 2022 | finance.yahoo.comUNITY Biotechnology to Participate in the Cowen 42nd Annual Health Care ConferenceFebruary 14, 2022 | finance.yahoo.comUNITY Biotech Stock Jumps On Additional Data From UBX1325 Trial In Vascular Eye DiseaseFebruary 14, 2022 | seekingalpha.comUNITY posts 24-week data from Phase 1 trial for UBX1325 in vascular eye diseasesFebruary 3, 2022 | seekingalpha.comUNITY Biotech falls 9% aftermarket on initiation of restructuring programFebruary 3, 2022 | finance.yahoo.comUNITY Biotechnology Announces Restructuring to Advance Corporate Strategy and Focus on Key Ophthalmology ProgramsFebruary 3, 2022 | finance.yahoo.comAnti-aging company Unity Biotechnology to axe half its staff, focus on eye drugsJanuary 4, 2022 | finance.yahoo.comUNITY Biotechnology Provides Program Updates and Anticipated Milestones for 2022December 29, 2021 | nasdaq.comUnity Biotechnology Inc Shares Fall 0.7% Below Previous 52-Week Low - Market MoverDecember 20, 2021 | finance.yahoo.comUNITY Biotechnology Announces Exclusive License Agreement with Jocasta Neuroscience to Continue Development of α-Klotho ProgramDecember 18, 2021 | finance.yahoo.comUnity Biotechnology, Inc. (UBX)See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:UBX CUSIPN/A CIK1463361 Webwww.unitybiotechnology.com Phone(650) 416-1192FaxN/AEmployees65Year FoundedN/ACompany Calendar Last Earnings5/10/2022Today7/04/2022Next Earnings (Estimated)8/09/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$6.40 High Stock Price Forecast$12.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+915.9%Consensus RatingBuy Rating Score (0-4)3 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$4.78 million Price / Sales9.12 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares69,169,000Free Float64,466,000Market Cap$43.58 million OptionableNot Optionable Beta0.55 Unity Biotechnology Frequently Asked Questions Should I buy or sell Unity Biotechnology stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Unity Biotechnology stock. View analyst ratings for Unity Biotechnology or view top-rated stocks. What is Unity Biotechnology's stock price forecast for 2022? 4 equities research analysts have issued 12 month price targets for Unity Biotechnology's shares. Their UBX stock forecasts range from $4.00 to $12.00. On average, they anticipate Unity Biotechnology's stock price to reach $6.40 in the next year. This suggests a possible upside of 915.9% from the stock's current price. View analysts' price targets for Unity Biotechnology or view top-rated stocks among Wall Street analysts. How has Unity Biotechnology's stock price performed in 2022? Unity Biotechnology's stock was trading at $1.46 at the beginning of 2022. Since then, UBX shares have decreased by 56.8% and is now trading at $0.63. View the best growth stocks for 2022 here. When is Unity Biotechnology's next earnings date? Unity Biotechnology is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for Unity Biotechnology. How were Unity Biotechnology's earnings last quarter? Unity Biotechnology, Inc. (NASDAQ:UBX) posted its quarterly earnings results on Tuesday, May, 10th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.02. View Unity Biotechnology's earnings history. Who are Unity Biotechnology's key executives? Unity Biotechnology's management team includes the following people: Dr. Anirvan Ghosh Ph.D., CEO & Director (Age 58, Pay $885.54k)Dr. Nathaniel E. David A.B., Ph.D., Co-Founder & Exec. Director (Age 54, Pay $40k)Ms. Lynne Marie Sullivan, CFO & Head of Corp. Devel. (Age 55, Pay $614.84k)Dr. Jamie Dananberg M.D., Chief Medical Officer (Age 64, Pay $635.79k)Dr. Jan M. van Deursen, FounderDr. Judith Campisi Ph.D., FounderMr. Daohong Zhou M.D., FounderMr. Nathan Guz Ph.D., VP of OperationsMr. Alexander Azoy, VP of Fin., Chief Accounting Officer, Controller & Principal Accounting Officer (Age 46)Dr. Przemyslaw Sapieha Ph.D., Chief Scientific Advisor Who are some of Unity Biotechnology's key competitors? Some companies that are related to Unity Biotechnology include BriaCell Therapeutics (BCT), Agronomics (ANIC), Arix Bioscience (ARIX), Circassia Group (CIR), Novacyt (NCYT), ImmunoPrecise Antibodies (IPA), Faron Pharmaceuticals Oy (FARN), Tiziana Life Sciences (TILS), Verseon (VSN), Scancell (SCLP), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), Aptose Biosciences (APS) and Arecor Therapeutics (AREC). View all of UBX's competitors. What other stocks do shareholders of Unity Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), (CGC), VBI Vaccines (VBIV), Enphase Energy (ENPH), Sorrento Therapeutics (SRNE) and OPKO Health (OPK). When did Unity Biotechnology IPO? (UBX) raised $85 million in an IPO on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager. What is Unity Biotechnology's stock symbol? Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX." How do I buy shares of Unity Biotechnology? Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Unity Biotechnology's stock price today? One share of UBX stock can currently be purchased for approximately $0.63. How much money does Unity Biotechnology make? Unity Biotechnology (NASDAQ:UBX) has a market capitalization of $43.58 million and generates $4.78 million in revenue each year. How many employees does Unity Biotechnology have? Unity Biotechnology employs 65 workers across the globe. How can I contact Unity Biotechnology? The official website for Unity Biotechnology is www.unitybiotechnology.com. The company can be reached via phone at (650) 416-1192. This page (NASDAQ:UBX) was last updated on 7/4/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
